Skip to main content

Advertisement

SpringerLink
Log in

Pergolide-associated valvular heart disease

  • Original Articles
  • Published:
Comprehensive Therapy

Abstract

Pergolide is an ergot derivative dopamine agonist used in the treatment of Parkinson's disease and restless legs syndrome. Ergot derivatives are known to be associated with fibrotic conditions, including a carcinoid-like, fibrotic, valvular heart disease (VHD). Recently, pergolide was identified in association with the development of VHD. This article includes a summary of the literature published on pergolide-associated VHD, a description of the potential mechanisms of drug-induced VHD, and the clinical implications for the management of patients taking pergolide.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337: 581–588.

    Article  PubMed  CAS  Google Scholar 

  2. Bana DS, MacNeal PS, LeCompte PM, et al. Cardiac murmurs and endocardial fibrosis associated with methysergide therapy. Am Heart J 1974;88:640–655.

    Article  PubMed  CAS  Google Scholar 

  3. Hendrikx M, Van Dorpe J, Flameng W, Daenen W. Aortic and mitral valve disease induced by ergotamine therapy for migraine: a case report and review of the literature. J Heart Valve Dis 1996;5:235–237.

    PubMed  CAS  Google Scholar 

  4. Redfield MM, Nicholson WJ, Edwards WD, Tajik AJ. Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations. Ann Intern Med 1992;117:50–52.

    PubMed  CAS  Google Scholar 

  5. Pritchett AM, Morrison, JF, Edwards WD, et al. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2002;77:1280–1286.

    PubMed  Google Scholar 

  6. Lang AE, Quinn N, Drincat S, et al. Pergolide in late-stage Parkinson's disease. Ann Neurol 1982;12:243–247.

    Article  PubMed  CAS  Google Scholar 

  7. Goldstein M, Lieberman A, Lew JY, et al. Interaction of pergolide with central dopaminergic receptors. Proc Natl Acad Sci USA. 1980;77:3725–3728.

    Article  PubMed  CAS  Google Scholar 

  8. Lieberman A, Goldstein M, Leibowitz M, et al. Treatment of advanced Parkinson's disease. Neurology 1981;31:675–682.

    PubMed  CAS  Google Scholar 

  9. Mizuno Y, Kondo T, Narabayashi H. Pergolide in the treatment of Parkinson's disease. Neurology 1995;45(suppl 3):S13-S21.

    PubMed  CAS  Google Scholar 

  10. Physician Desk Reference. 60th Edition. Montvale, NJ: Thomson PDR; 2006.

  11. Facca A, Sanchez-Ramos J. High dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias. Mov Disord 1996;11:327–329

    Article  PubMed  CAS  Google Scholar 

  12. Schwarz J, Scheidtmann K, Trenkwalder C. Improvement of motor fluctuations in patients with Parkinson's disease following treatment with high doses of pergolide and cessation of levodopa. Eur Neur 1997;37:236–238.

    Article  CAS  Google Scholar 

  13. Trenkwalder C, Winkelemann J, Hundemer HP, et al. High-dose treatment of Parkinson's disease with pergolide. Mov Disord. 2000;15:132. Abstract.

    Google Scholar 

  14. Wetter TC, Stiasny K, Winkelmann, et al. A Randomized controlled study of pergolide in patients with restless legs syndrome. Neurology 1999;52:944–950.

    PubMed  CAS  Google Scholar 

  15. Berezin M, Avidan D, Baron E. Long-term pergolide treatment of hyperprolactinemic patients previously unsuccessful treated with dopaminergic drugs. Isr J Med Sci 1991;27(7):375–379.

    PubMed  CAS  Google Scholar 

  16. Pfitzenmeyer P, Foucher P, Dennewald G, et al. Pleuropulmonary changes induced by ergoline drugs. Eur Respir J 1996;9:1013–1019.

    Article  PubMed  CAS  Google Scholar 

  17. Siberstein SD. Methysergide. Cephalalgia 1998;18:421–435.

    Article  Google Scholar 

  18. Shaunak S, Wilkins A, Piling JB, Dick DJ. Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide. J Neurol Neurosurg Psychiatry 1999;66:79–81.

    PubMed  CAS  Google Scholar 

  19. Hoffman W, Trippel O. Retroperitoneal fibrosis aetiological considerations. J Urol 1961;86:222–232.

    PubMed  CAS  Google Scholar 

  20. Danoff SK, Grasso Ma, Terry PB, Flynn JA. Pleuropulmonary Disease due to pergolide use for restless legs syndrome. Chest 2001; 120:313–316.

    Article  PubMed  CAS  Google Scholar 

  21. Morin, LJ, Zuerner, RT. Retroperitoneal fibrosis and carcinoid tumor. JAMA 1971;216:1647.

    Article  PubMed  CAS  Google Scholar 

  22. Jimenez-Jimenez FJ, Lopez-Alvarez J, Sanchez-Chapado M, et al. Retroperitoneal fibrosis in a patient with Parkinson's disease treated with pergolide. Clin Neuropharmacol 1995;18:277–279.

    Article  PubMed  CAS  Google Scholar 

  23. Bleumink GS, van der Molen-Eijgenraam M, Strijbos JH, et al. Pergolide-induced Pleuropulmonary fibrosis. Clin Neuropharmacol 2002;25:290–293.

    Article  PubMed  CAS  Google Scholar 

  24. Serratrice J, Disdier P, Habib G, et al. Fibrotic heart disease subsequent to bromocriptine treatment. Cardiology in Review 2002;10:334–336.

    Article  PubMed  Google Scholar 

  25. Flowers CM, Racoosin JA, Lu SL, et al. The US Food and Drug Administration's Registry with pergolide-associated valvular heart disease. Mayo Clin Proc 2003;78:730–731.

    PubMed  Google Scholar 

  26. Robiolio PA, Rigolin VH, Wilson JS, et al. Carcinoid heart disease: correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 1995;92:790–795.

    PubMed  CAS  Google Scholar 

  27. Rothman RB, Baumann MH, Savage JE, et al. Evidence for possible involvement of 5-HT2B receptors in cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000;102:2836–2841.

    PubMed  CAS  Google Scholar 

  28. Setola V, Hufeisen SJ, Grande-Allen KJ, et al. 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) induces fenfluramine-like proliferative actions on human valvular interstitial cells in vitro. Mol Pharmacol 2003;63:1223–1229.

    Article  PubMed  CAS  Google Scholar 

  29. Van Camp GV, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. The Lancet 2004;363:1179–1183.

    Article  CAS  Google Scholar 

  30. Baseman DG, O'Suilleabhain PE, Reimold SC, et al. Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology 2004;63:301–304.

    PubMed  CAS  Google Scholar 

  31. Waller EA, Kaplan J, Heckman MG. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2005;80(8):1016–1020.

    PubMed  CAS  Google Scholar 

  32. Singh JP, Evans JC, Levy D, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (The Framingham Heart Study). Am J Cardiol 1999;83:897–902.

    Article  PubMed  CAS  Google Scholar 

  33. Burger AJ, Charlamb MJ, Singh S, et al. Low risk of significant valvulopathy in patients treated with anorectic drugs. Int J Cardiol 2001;71:159–165.

    Article  Google Scholar 

  34. Gardin JM, Schumacher D, Constantine G, et al. Valvular Abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA 2000;283:1703–1709.

    Article  PubMed  CAS  Google Scholar 

  35. Jollis JG, Landolfo CK, Kisslo J, et al. Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. Circulation 2000;101: 2071–2077.

    PubMed  CAS  Google Scholar 

  36. Kancherla, MK, Salti HI, Mulderink, TA, et al. Echocardiographic prevalence of mitral and/or Aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine. Am J Cardiol 1999;84:1335–1338.

    Article  PubMed  CAS  Google Scholar 

  37. Teramae CY, Connolly HM, Grogan M, and Miller FA. Diet Drug related cardiac valve disease: The Mayo Clinic echocardiographic laboratory experience. Mayo Clin Proc 2000;75:456–461.

    PubMed  CAS  Google Scholar 

  38. Van Camp GV, Falmez A, Cosyns B, et al. Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide. Neurology 2003;61:859–861.

    PubMed  Google Scholar 

  39. Hensrud BB, Connolly HM, Grogan M, et al. Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine. Mayo Clin Proc 1999;74:1191–1197.

    Article  PubMed  CAS  Google Scholar 

  40. Horvath J, Fross RD, Kleiner-Fisman G, et al. Severe multivalvular heart disease: and new complication of the ergot derivative dopamine agonist. Mov Disorders 2004;19:656–662.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Mayo Clinic, Davis Building E7A, 4500 San Pablo Road, 32256, Jacksonville, FL

    E. Andrew Waller & Joseph Kaplan MD

Authors
  1. E. Andrew Waller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joseph Kaplan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph Kaplan MD.

Additional information

The authors have stated that they do not have a significant financial interest or other relationship with any product manufacturer or provider of services discussed in this article. The authors do not discuss the use of off-label products, which includes unlabeled, unapproved, or investigative products or devices.

About this article

Cite this article

Waller, E.A., Kaplan, J. Pergolide-associated valvular heart disease. Compr Ther 32, 94–101 (2006). https://doi.org/10.1385/COMP:32:2:94

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1385/COMP:32:2:94

Keywords

Search

Navigation